for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allogene Therapeutics Inc

ALLO.OQ

Latest Trade

34.70USD

Change

1.72(+5.22%)

Volume

220,980

Today's Range

33.58

 - 

35.55

52 Week Range

17.49

 - 

54.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
32.98
Open
34.30
Volume
220,980
3M AVG Volume
18.72
Today's High
35.55
Today's Low
33.58
52 Week High
54.90
52 Week Low
17.49
Shares Out (MIL)
140.28
Market Cap (MIL)
4,626.44
Forward P/E
-15.63
Dividend (Yield %)
--

Next Event

Iovance Biotherapeutics Inc, Warburg Pincus LLC, Allogene Therapeutics Inc, ArsenalBio, Tmunity Therapeutics Inc, Medigene AG, and Atara Biotherapeutics Inc at Alliance for Regenerative Medicine Immuno-Oncology 360 Conference (Virtual) - Panel

Latest Developments

More

Allogene Therapeutics Receives Ind Clearance From The U.S. Food And Drug Administration For Allo-715 In Combination With Nirogacestat In Relapsed/Refractory Multiple Myeloma

Allogene, Overland Form JV In Greater China To Develop, Commercialize AlloCAR T Cell Therapies

Allogene Therapeutics Announces Preclinical Findings Supporting Allo-605, First Anti-Bcma Turbocar T Cell Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Industry

Biotechnology & Drugs

Contact Info

210 E Grand Ave

SOUTH SAN FRANCISCO, CA

94080-4811

United States

+1.650.4572700

http://www.allogene.com/

Executive Leadership

Arie S. Belldegrun

Executive Chairman of the Board

David Chang

President, Chief Executive Officer, Co-Founder, Director

Joshua A. Kazam

Co-Founder, Director

Eric T. Schmidt

Chief Financial Officer

Rafael G. Amado

Executive Vice President - Research and Development, Chief Medical Officer

Key Stats

1.75 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-7.310

2019

-1.830

2020(E)

-2.109
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-26.46
Return on Equity (TTM)
-25.31

Latest News

Latest News

BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

* ALLOGENE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Allogene Therapeutics Commences Public Offering Of Common Stock

* ALLOGENE THERAPEUTICS ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Allogene Therapeutics, With Collaborator Servier, Reports Positive Results From Its Phase 1 Alpha Study Of Allo-501 In Relapsed/Refractory Non-Hodgkin Lymphoma

* ALLOGENE THERAPEUTICS, WITH COLLABORATOR SERVIER, REPORTS POSITIVE RESULTS FROM ITS PHASE 1 ALPHA STUDY OF ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

U.S. RESEARCH ROUNDUP-CVS Health, Regal Beloit, Zuora

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CVS Health, Regal Beloit and Zuora, on Thursday. HIGHLIGHT * CVS Health Corp : Credit Suisse raises to outperform from neutral * Dow Inc : HSBC cuts to hold...

BRIEF-Allogene Therapeutics Expects To Initiate Enrollment In Phase 1 Lymphoma Trial In Q2 2020

* AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ABSTRACT REPORTS INITIAL ALLO-501 ALPHA PHASE 1 DATA IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies

Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight...

BRIEF-Allogene Therapeutics Q1 Loss Per Share $0.50

* ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies

* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES

BRIEF-Allogene Therapeutics Reports Q4 Loss Of $0.58 Per Share

* ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, oil stocks, Big Lots, Exxon Mobil, Costco

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added...

Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's <MRNA.O> shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.

Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in the U.S. markets spurred by investors fretting over an economic slowdown.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up